Kailera Therapeutics, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Kailera Therapeutics, Inc. (KLRA) holds an ST Score of 64.3 out of 100 (B), with its strongest factor being Valuation (A) and its weakest Momentum (D). KLRA last traded at $12.83.
- Strongest
- ValuationA
- Weakest
- MomentumD
All factor grades
- ValuationA
- Financial StrengthA
- ForecastA
- ProfitabilityB+
- GrowthC-
- MomentumD
Contact
KLRA stock: frequently asked questions
What is KLRA's ST Score?
Kailera Therapeutics, Inc. (KLRA) has an ST Score of 64.3 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is KLRA a buy, sell, or hold?
Our own ST Score grades it B (64.3/100). This is data, not investment advice — always do your own research.
What is KLRA's valuation grade?
Kailera Therapeutics, Inc. (KLRA) earns a valuation grade of A, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is KLRA's growth grade?
Kailera Therapeutics, Inc. (KLRA) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is KLRA's profitability grade?
Kailera Therapeutics, Inc. (KLRA) earns a profitability grade of B+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is KLRA's financial strength grade?
Kailera Therapeutics, Inc. (KLRA) earns a financial strength grade of A, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for KLRA?
The average analyst price target for Kailera Therapeutics, Inc. (KLRA) is $42.00, which is +2.3% versus the recent price of $12.83.